Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average) (2017 - 2026)

Crinetics Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $104.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 11.81% year-over-year to $104.1 million; the trailing twelve-month figure through Mar 2026 stood at $104.1 million (up 11.81% YoY), and the FY2025 full-year result was $94.1 million, up 16.43% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $104.1 million, up from $94.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $104.1 million in Q1 2026, with the low at $47.7 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $71.5 million, with a median of $72.3 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) soared 49.86% in 2022 and grew 2.99% in 2023.
• Tracing CRNX's Shares Outstanding (Weighted Average) over 5 years: stood at $52.0 million in 2022, then rose by 11.71% to $58.1 million in 2023, then surged by 39.11% to $80.8 million in 2024, then climbed by 16.43% to $94.1 million in 2025, then grew by 10.68% to $104.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $104.1 million (Q1 2026), $94.1 million (Q4 2025), and $93.7 million (Q3 2025), per Business Quant data.

Peer Comparison